2013 News Releases

Webcast ImageWebcast
Neuralstem, Inc at BIO CEO & Investor Conference (Replay)
02/13/17 at 8:30 a.m. ET
Webcast ImageWebcast
Neuralstem, Inc. at 29th Annual ROTH Conference (Replay)
03/13/17 at 12:00 p.m. PT
Webcast ImageWebcast
Neuralstem, Inc. at Oppenheimer 27th Annual Healthcare Conference (Replay)
03/21/17 at 1:00 p.m. ET
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
11/12/13Neuralstem Reports Third Quarter Financial Results And Provides Business And Clinical Update
ROCKVILLE, Md., Nov. 12, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported  financial results for the three months and nine months ended September 30, 2013 and provided a business and clinical update. "The Company reached several major milestones in the third quarter. We completed patient dosing in our Phase Ib trial to treat major depressive disorder with NSI-189, our lead small molecule compound. We also commenced a multicenter Phase II cell therapy trial with NS... 
Download PDFPrinter Friendly Version
10/10/13Dr. Eva Feldman, Principal Investigator, to Give Update on ALS Trial at American Neurological Association Meeting
ROCKVILLE, Md., Oct. 10, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that Eva Feldman, MD, PhD, principal investigator of the Phase II trial testing Neuralstem's spinal cord stem cells, NSI-566, in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), will speak at the American Neurological Association's (ANA) Annual Meeting in New Orleans, LA, on October 15th at 1:35 (http://www.aneuroa.org/i4a/pages/index.cfm?pageid=3752). Dr. Feldman, who is al... 
Download PDFPrinter Friendly Version
10/09/13University Of Michigan Health System Treats Its First Patients In Neuralstem's Phase II ALS Stem Cell Trial
First of Five Cohorts Completed in Dose Escalation Trial ROCKVILLE, Md., Oct. 9, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the University of Michigan Health System, in Ann Arbor, Michigan, treated its first two patients in the Phase II trial testing NSI-566 neural stem cells in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). This completes the first cohort in Phase II, which is also being conducted at Emory University Hospital, in Atlanta, Geo... 
Download PDFPrinter Friendly Version
09/26/13Neuralstem CEO To Present At Stem Cells & Regenerative Medicine Congress
Ted Harada, ALS Stem Cell Trial Patient, To Talk ROCKVILLE, Md., Sept. 26, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO, Richard Garr, will present at the Stem Cells & Regenerative Medicine Congress, on Monday, September 30 at 12:00 PM at the Hyatt Regency in Cambridge, MA (http://www.terrapinn.com/2013/stem-cells-usa-regenerative-medicine/index.stm). Mr. Garr will give an overview of Neuralstem's ongoing trial testing NSI-566 stem cells... 
Download PDFPrinter Friendly Version
09/10/13First Patient Treated In Phase II Of Neuralstem ALS Stem Cell Trial
ROCKVILLE, Md., Sept. 10, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at Emory University Hospital in Atlanta, Georgia. The Phase II dose escalation and safety trial, taking place at Emory and at the University of Michigan Health System, is designed to treat up to 15 patients in five differ... 
Download PDFPrinter Friendly Version
09/05/13Neuralstem To Raise $4 Million In Registered Direct Offering
ROCKVILLE, Md., Sept. 5, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced today that it has entered into agreements with certain accredited investors for a registered direct placement of 2,535,000 shares of common stock at a price of $1.60 per share for aggregate gross proceeds of $4,056,000. In addition, the Company will issue to each investor a warrant to purchase a number of shares of common stock equal to one-half of the number of shares purchased by the investor in the ... 
Download PDFPrinter Friendly Version
09/03/13Neuralstem President And CEO To Present At The 2013 Rodman & Renshaw Annual Healthcare Conference
Live Webcast on Tuesday, September 10, at 11:40 a.m. EST ROCKVILLE, Md., Sept. 3, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 15th annual Rodman & Renshaw Healthcare Conference on Tuesday, September 10, at 11:40 a.m. EST, in Room 7.03, 7th Floor, of the Millennium Broadway Hotel in New York City. Garr will provide an overview of the company's upcoming NSI-566 cell therapy clinical trials, including ALS Phase ... 
Download PDFPrinter Friendly Version
08/09/13Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update
ROCKVILLE, Md., Aug. 9, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months ended June 30, 2013 and provided a business and clinical update. "The focus of the second quarter was preparation for the start of several trials, both in the U.S. and internationally, in the second half of the year. We expect to begin our NSI-566 ALS Phase II trial in August or September, at both Emory and the University of Michigan. The trial, with... 
Download PDFPrinter Friendly Version
08/01/13Neuralstem Cells Reverse Cognitive Defect In Brain-Irradiated Rats, University Of California Irvine Paper Shows
ROCKVILLE, Md., Aug. 1, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that a paper published in the journal "Cell Transplantation  - The Regenerative Medicine Journal," reported that Neuralstem's spinal cord-derived human neural stem cells, NSI-566, improved cognitive function in rats who'd received radiation to the brain, as assessed by two separate cognitive tasks (http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct1048acharya ). In the paper, "Transplantatio... 
Download PDFPrinter Friendly Version
06/10/13Neuralstem ALS Trial Principal Investigator, Dr Eva Feldman, Gives Grand Plenary Address At The Canadian Neurological Sciences Federation Annual Congress
Will Present Final ALS Phase I Results Including New Cervical Cohort Data ROCKVILLE, Md., June 10, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported that Eva Feldman, MD, PhD, will address the Canadian Neurological Sciences Federation Annual Congress, in Montreal, Canada, on Thursday, June 13th at 8:30 a.m. ET as a grand plenary speaker (http://congress.cnsfederation.org/). Dr. Feldman will present final data from Neuralstem's Phase I trial testing NSI-566 spinal cord-... 
Download PDFPrinter Friendly Version
05/28/13Neuralstem's Cells Induce Improvement In Acute Spinal Cord Injury Rats, UCSD Study Shows
ROCKVILLE, Md., May 28, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that a paper published today in the journal, STEM CELL RESEARCH AND THERAPY http://stemcellres.com/, showed that rats transplanted with its spinal cord-derived human neural stem cells, NSI-566, three days after a spinal cord injury at L3 (lumbar 3), showed improvement along several measures of motor function and a reduction of spasticity. The study, "Amelioration of Motor/Sensory Dysfunction and Spasticity in... 
Download PDFPrinter Friendly Version
05/20/13Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania
Data Shows, Early Stem Cell Transplantation Could Slow Progression Or Even Improve Patient's Condition in Some Forms of ALS ROCKVILLE, Md., May 20, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported that Eva Feldman, MD, PhD, principal investigator, presented updated Phase I data from its spinal cord-derived human neural stem cell (NSI-566) trial in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at the neuro diabetes special medical s... 
Download PDFPrinter Friendly Version
05/16/13Neuralstem CEO, Richard Garr, To Present At Annual World Stem Cells And Regenerative Medicine Congress In London
ROCKVILLE, Md., May 16, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that CEO and President, Richard Garr, will present at the Annual World Stem Cells and Regenerative Medicine Congress on Thursday, May 23, in London, UK.  Mr. Garr's talk, "Understanding the Practicalities of Using Innovative Therapies on Patients," at 2:05 PM, will explore how cell therapies will be used by clinicians and integrated into hospital settings (http://www.terrapinn.com/2013/stemcells/spe... 
Download PDFPrinter Friendly Version
05/13/13Neuralstem Principal Investigator, Dr. Eva Feldman, Presents Phase I ALS Trial Data At The Romanian Neurological Society Congress
ROCKVILLE, Md., May 13, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported that Eva Feldman, MD, PhD, principal investigator, will present updated Phase I data from the trial using NSI-566 spinal cord-derived human neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at the Romanian Neurological Society Congress held in Bucharest, Romania, on May 17th.  In a talk called "Recent Therapeutic Advances in Stem Cell Therapy," Dr... 
Download PDFPrinter Friendly Version
05/10/13Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
ROCKVILLE, Md., May 10, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today reported its financial results for the three months ended March 31, 2013 and provided a business and clinical update. "The Company continues to progress all of its clinical trial programs, in the U.S. and abroad, as we move into 2013. The FDA has approved our Phase II trial protocol for NSI-566/ALS, which we expect to initiate this summer. The protocol calls for an aggressive dose escalation strategy and a... 
Download PDFPrinter Friendly Version
05/08/13Neuralstem ALS Trial Investigator And Patient On Sirius XM
Dr. Eva Feldman and Ted Harada to discuss Neuralstem ALS Trial ROCKVILLE, Md., May 8, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that Eva Feldman, MD, PhD, principal investigator of the Phase II trial using NSI-566 spinal cord-derived human neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), will be a guest on Sirius XM's Doctor Radio station, channel 81, on Thursday, May 9, 10-11am EDT. Dr. Feldman will be on "Beyond th... 
Download PDFPrinter Friendly Version
04/29/13Neuralstem ALS Trial Data Presented At The American Association Of Neurological Surgeons Annual Meeting
Method of intraspinal cell delivery found to be safe, well-tolerated, and promising for other spinal cord conditions ROCKVILLE, Md., April 29, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that final data on the intraspinal delivery method employed in its NSI-566 Phase I trial to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) was presented today at the American Association of Neurological Surgeons Annual Meeting. In a presentation called "Intraspinal ... 
Download PDFPrinter Friendly Version
04/22/13FDA Approves Neuralstem To Treat Final Cohort In NSI-189 Phase Ib Trial In Major Depressive Disorder
ROCKVILLE, Md., April 22, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it has received approval from the Food and Drug Administration (FDA) to begin dosing the third and final cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder (MDD). NSI-189, the lead compound in Neuralstem's neurogenic small molecule platform, is a proprietary new chemical entity that stimulates new neuron growth in the hippocampus,... 
Download PDFPrinter Friendly Version
04/18/13Neuralstem CEO, Richard Garr, To Participate In Traumatic Brain Injury Panel At BIO International Convention
ROCKVILLE, Md., April 18, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that CEO and President, Richard Garr, will take part in a comprehensive Bio Maryland panel, introduced by Lt. Governor, Anthony Brown, on Maryland's leadership in traumatic brain injury prevention, diagnosis and treatment at the BIO International Convention in Chicago, Ill., on April 24. Mr. Garr's panel, from 2:30 – 3:30, will discuss "Treatment—What's Working and What is Under Development." He will f... 
Download PDFPrinter Friendly Version
04/17/13Neuralstem Receives FDA Approval To Commence Phase II Stem Cell Trial In Amytrophic Lateral Sclerosis
Trial Expands to Two Centers; Approval Includes Significant Increase in Dosing ROCKVILLE, Md., April 17, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it has received approval from the Food and Drug Administration (FDA) to commence a Phase II trial using NSI-566 spinal cord-derived human neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). This Phase II dose escalation and safety trial will expand to two centers, Emory ... 
Download PDFPrinter Friendly Version
04/05/13Neuralstem Receives Notice Of Allowance Of Patent Covering Use Of Stem Cells To Treat Amyotrophic Lateral Sclerosis
ROCKVILLE, Md., April 5, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced today that it received a notice of allowance for patent application 12/404,841. This patent covers methods for treating amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) with expanded spinal cord stem cells, including NSI-566. Neuralstem completed a Phase I safety trial of its NSI-566 stem cells in ALS earlier this year, for which it has also been granted an Orphan Drug Designation. ... 
Download PDFPrinter Friendly Version
03/25/13Neuralstem Secures $8 Million In Debt Financing From Hercules
ROCKVILLE, Md., March 25, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced today that it secured $8 million in debt financing with Hercules Technology Growth Capital (NYSE: HTGC), to fund the company's capital budget through late 2014. "This debt financing extends our cash runway well into late 2014 at a critical time in our clinical product development cycle. We have multiple NSI-566 cell therapy clinical trials planned this year, building on our successful ALS Phase I tria... 
Download PDFPrinter Friendly Version
03/15/13Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
ROCKVILLE, Md., March 15, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today provided an update on its clinical trial programs and reported its 2012 financial results for the year ended December 31, 2012. "2012 saw the company achieve success in all of its Phase I clinical trial objectives," said Karl Johe, Ph.D., Neuralstem's Chairman of the Board and Chief Scientific Officer. "We have been able to demonstrate the safety and tolerability of Neuralstem's novel core technologies, f... 
Download PDFPrinter Friendly Version
03/14/13Neuralstem CEO, Richard Garr, Named To "Top 50 Global Stem Cell Influencers"
ROCKVILLE, Md., March 14, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that CEO and President, Richard Garr, was listed as the 15th most influential person in the stem field in  the "Top 50 Global Stem Cell Influencers," published by Total BioPharma,  a division of Terrapinn, in advance of the World Stem Cells & Regenerative Medicine Congress 2013, in May. The list is the result of a global stem cell community survey to determine the most influential indivi... 
Download PDFPrinter Friendly Version
02/20/13Neuralstem Grants Licenses For Central Nervous System Therapy Surgical Devices To Cedars-Sinai Medical Center
ROCKVILLE, Md., Feb. 20, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it has granted licenses to intellectual property surrounding its spinal cord delivery platform, floating cannula, and method for delivering therapeutic agents to the spinal cord to Cedars-Sinai Medical Center, a non-profit academic medical center located in Los Angeles, CA. The license agreements grant Cedars-Sinai Medical Center the non-exclusive right to use the licensed intellectual property i... 
Download PDFPrinter Friendly Version
02/07/13Neuralstem President And CEO To Present At BIO CEO & Investor Conference 2013
Live Webcast to Air on Tuesday, February 12, at 9:30 a.m. EST ROCKVILLE, Md., Feb. 7, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 15th Annual BIO CEO & Investor Conference 2013 in New York City on Tuesday, February 12, at 9:30 a.m. EST, in the Duke of Windsor Room at The Waldorf Astoria Hotel. Garr will present an update on the company's NSI-566 cell therapy clinical trials, including the FDA-approved ch... 
Download PDFPrinter Friendly Version
01/14/13Neuralstem Receives FDA Approval To Commence Spinal Cord Injury Trial
NSI-566 to be tested in patients with chronic spinal cord injury ROCKVILLE, Md., Jan. 14, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it received approval from the United States Food and Drug Administration (FDA) to commence a Phase I safety trial of its lead cell therapy candidate, NSI-566, in chronic spinal cord injury patients. This open-label, multi-site study, will enroll up to eight patients with thoracic spinal cord injuries (T2-T12), who have an American Spina... 
Download PDFPrinter Friendly Version
01/04/13Neuralstem President and CEO to Present 2013 Trials Overview at 2013 Biotech Showcase
Updates on Upcoming ALS Phase II - NSI-189 Phase Ib - Stroke Phase I/II in China Live Audio Webcast to Air on Tuesday, January 8, at 3:45 p.m. PT ROCKVILLE, Md., Jan. 4, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the fifth annual Biotech Showcase in San Francisco on Tuesday, January 8, 3:45 p.m. PT, in Room Powell. Garr will present a business overview, including a first look at the Phase I/II Stroke/NSI-566 cell... 
Download PDFPrinter Friendly Version